Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms

Ilan Guedj, David Scharfstein

NBER Working Paper No. 10933
Issued in November 2004
NBER Program(s):Corporate Finance, Productivity, Innovation, and Entrepreneurship

This paper compares the clinical trial strategies and performance of large, established ("mature") biopharmaceutical firms to those of smaller ("early stage") firms that have not yet successfully developed a drug. We study a sample of 235 cancer drug candidates that entered clinical trials during the period 1990-2002 and were sponsored by public firms. Early stage firms are more likely than mature firms to advance drug candidates from Phase I to Phase II clinical trials. However, early stage firms have much less promising clinical results in their Phase II trials and their Phase II drug candidates are also less likely to advance to Phase III and to receive Food and Drug Administration approval. This pattern is more pronounced for early stage firms with large cash reserves. The evidence points to an agency problem between shareholders and managers of single-product early stage firms who are reluctant to abandon development of their only viable drug candidates. By contrast, the managers of mature firms with multiple products in development are more willing to drop unpromising drug candidates. The findings appear to be consistent with the benefits of internal capital markets identified by Stein (1997).

download in pdf format
   (276 K)

email paper

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w10933

Users who downloaded this paper also downloaded* these:
Trusheim, Aitken, and Berndt w16014 Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
Scharfstein w6352 The Dark Side of Internal Capital Markets II: Evidence from Diversified Conglomerates
Danzon, Epstein, and Nicholson w10536 Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
Chan, Karolyi, and Stulz w4074 Global Financial Markets and the Risk Premium on U.S. Equity
Gromb and Scharfstein w9001 Entrepreneurship in Equilibrium
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us